[go: up one dir, main page]

EP0831803A1 - Sorbinsäure haltige hydrogele - Google Patents

Sorbinsäure haltige hydrogele

Info

Publication number
EP0831803A1
EP0831803A1 EP96917458A EP96917458A EP0831803A1 EP 0831803 A1 EP0831803 A1 EP 0831803A1 EP 96917458 A EP96917458 A EP 96917458A EP 96917458 A EP96917458 A EP 96917458A EP 0831803 A1 EP0831803 A1 EP 0831803A1
Authority
EP
European Patent Office
Prior art keywords
sorbic acid
hydrogel
pharmaceutical preparations
weight
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96917458A
Other languages
German (de)
English (en)
French (fr)
Inventor
Karin Hoffmann
Jutta Riedl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0831803A1 publication Critical patent/EP0831803A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Definitions

  • the invention relates to pharmaceutical preparations in the form of a hydrogel, which are characterized in that they contain sorbic acid, if appropriate in combination with a polyhydric alcohol and / or a polyhydric ether, as the sole active ingredients.
  • these preparation forms can contain polyhydric alcohols and / or polyhydric ethers, such as, for example, ethylene glycol, propylene glycol, glycerol or a polyoxyalkylene, which serve to prevent the skin from drying out and to keep it supple (humefectant, emolliant and softening agents) (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., VCH-Verlagsgesellschaft mbH, D-69451 Weinheim (DE), 1993, Volume AlO, p lOlff, Volume A21, p 579ff and Volume A22, p 163)
  • these additives can also serve as agents for enhancing the penetration of the active ingredients (enhancers).
  • Suitable polyvalent alcohols and / or polyvalent ethers for the pharmaceutical preparations according to the invention are preferably physiologically harmless, liquid substances of these classes of substances, as are usually used in such preparations.
  • Such compounds are, for example, those of the general formula II
  • n is a number from 1 to 12 (preferably 1 to 8) and
  • R is a hydrogen atom, a methyl group or, if n is 1, also a
  • Suitable alcohols or ethers of the general formula I are, for example, ethylene glycol, propylene glycol, glycerol, diethylene glycol, triethylene glycol, dipropylene glycol or tripropylene glycol. These are substances which are also used in pharmaceutical preparations intended for topical application as enhancers for the active ingredients used in the preparations (see, for example, EP-A 0 165 696, WO 88/01496 and DE-A 2 515 594).
  • the pharmaceutical preparations according to the invention can also contain, for example, cyclic polyols or polyethers such as dimethyl isosorbide or glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • cyclic polyols or polyethers such as dimethyl isosorbide or glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • propylene glycol has proven to be particularly suitable.
  • the pharmaceutical preparations according to the invention in the form of a hydrogel can contain, for example, 0.05 to 2.5% by weight and preferably 0.1 to 1.0% by weight of sorbic acid and 0 to 30% by weight and preferably 5 to 20% by weight of a polyvalent Contain alcohol and / or a polyvalent ether.
  • Suitable thickeners are, for example, gel-forming polysaccharides and proteins such as gelatin, agar-agar, pectins, and dextrins or in particular polyacrylates, such as those of the Carbopol® type (Goodrich Chem., Cleveland, USA).
  • a suitable preparation in the form of a hydrogel can have, for example, the following composition:
  • Carbopol® 980 0.5 2.0%
  • sorbic acid 12.0 g of propylene glycol and 76.55 g of purified water are mixed, heated to 35 ° C. and the sorbic acid is dissolved with stirring. The solution is then cooled to 20 ° C., 1.0 g of Carbopol® are added and the mixture is homogenized. A solution of 10.0 g of sodium hydroxide in 10.25 g of purified water is then added to the mixture and the mixture is homogenized until the gel structure has completely formed.
  • the developed hydrogel base with sorbic acid also shows a strong antimicrobial activity and a clear influence on the inflammation process in acne, which goes far beyond the expected vehicle effect of a preserved hydrogel base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96917458A 1995-05-31 1996-05-30 Sorbinsäure haltige hydrogele Withdrawn EP0831803A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19520838 1995-05-31
DE19520838 1995-05-31
PCT/EP1996/002300 WO1996038135A1 (de) 1995-05-31 1996-05-30 Sorbinsäure haltige hydrogele

Publications (1)

Publication Number Publication Date
EP0831803A1 true EP0831803A1 (de) 1998-04-01

Family

ID=7763859

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917458A Withdrawn EP0831803A1 (de) 1995-05-31 1996-05-30 Sorbinsäure haltige hydrogele

Country Status (12)

Country Link
EP (1) EP0831803A1 (cs)
JP (1) JPH11506441A (cs)
KR (1) KR19990022143A (cs)
CN (1) CN1185735A (cs)
AU (1) AU6002796A (cs)
CA (1) CA2222566A1 (cs)
CZ (1) CZ374797A3 (cs)
HU (1) HUP9801745A3 (cs)
IS (1) IS4606A (cs)
PL (1) PL323598A1 (cs)
TR (1) TR199701463T1 (cs)
WO (1) WO1996038135A1 (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
BE1023757B1 (nl) * 2016-06-30 2017-07-12 Yun NV Bewaring van micro-organismen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333314A (ja) * 1986-07-29 1988-02-13 Sansho Seiyaku Kk 外用剤
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9638135A1 *

Also Published As

Publication number Publication date
PL323598A1 (en) 1998-04-14
IS4606A (is) 1997-10-31
JPH11506441A (ja) 1999-06-08
CA2222566A1 (en) 1996-12-05
KR19990022143A (ko) 1999-03-25
AU6002796A (en) 1996-12-18
CZ374797A3 (cs) 1998-04-15
TR199701463T1 (en) 1998-02-21
HUP9801745A2 (hu) 1998-12-28
HUP9801745A3 (en) 2000-04-28
CN1185735A (zh) 1998-06-24
WO1996038135A1 (de) 1996-12-05

Similar Documents

Publication Publication Date Title
DE3872521T3 (de) Steroide enthaltende flüssigkeit.
DE3783683T2 (de) Hautpenetration verbessernde zusammensetzungen.
EP0135617B1 (de) Indomethacin enthaltende, gelartige Salbe
DE10361022A1 (de) Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
DE69320968T2 (de) Neue bioaktive zusammensetzungen, ihre herstellung und verwendung
EP0609796A2 (de) Blondiermittel für menschliche Haare
EP0108318A1 (de) Zahn- und Mundpflegemittel
DE3027933A1 (de) Pharmazeutische zubereitung auf der grundlage von heidelbeerextrakten
DE69117800T2 (de) Xylobiose enthaltende Zusammensetzung
DE69907656T2 (de) Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung
DE69118327T2 (de) Topisch anzuwendende Niclosamid enthaltende Lotion
CH676549A5 (cs)
DE69000843T2 (de) Dermatologische und kosmetische zusammensetzungen auf der basis von alkoylcarboxamid und zink-salzen zur behandlung von seborrhoid-dermatitis und/oder von seborrhoid-stoerungen.
EP0831803A1 (de) Sorbinsäure haltige hydrogele
DE2504615C3 (de) Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und Neomycin
EP0450123B1 (de) Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung
DE69232014T2 (de) Amethocain enthaltende Arzneimittel
DE2812117A1 (de) Neuartige bis-aminmonofluorphosphate, verfahren zu deren herstellung sowie deren verwendung in karies verhindernden mischungen
DE3339196A1 (de) Antimikrobielles konservierungs- und desinfektionsmittel
DE3049038C2 (cs)
DE4304303C2 (de) Vitamin-E-Derivate mit einem quartären Stickstoffatom, Verfahren zu deren Herstellung und kosmetische Mittel enthaltend dieselben
DE2847975A1 (de) Verfahren zur bindung von freiem formaldehyd in pharmazeutischen und kosmetischen zubereitungen
EP0555634A2 (de) Desinfektionsmittel
DE2416556A1 (de) Hautpflege- und hautschutzmittel mit einem gehalt an hautfeuchthaltemitteln
DE1962969C3 (de) Lichtschutzmittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990730